![b65280e1-](https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2018/09/1200/675/rabies661.jpg?ve=1&tl=1)
Drugmaker Kamada Ltd said its rabies therapy had met the main goal in a large study, where it was found to be non-inferior to a reference product.
The drug, KamRab, is being developed as a post-exposure treatment for rabies and is already marketed in 10 countries worldwide, the company said on Wednesday.
Kamada plans to file for a marketing approval for the drug in the United States by mid-2016.